JNJ
Stock Market Outlook for 2021
By Valuentum Analysts February 8, 2021 2020 was one for the history books. We covered our thoughts and reflections on the past year in our “2020 Won’t Soon Be Forgotten” article (link here), and now we are looking towards the future. Global health authorities should be able to bring an end to the ongoing coronavirus (‘COVID-19’) pandemic sooner than many had expected as several vaccines have already been improved for emergency use and several others appear increasingly likely to get approved. Global vaccine distribution activities are currently underway, and this should allow the world to slowly return to pre-pandemic activities. Before then, immense stimulus measures launched primarily in developed nations should support global economic activities until the public health crisis … Read more
Generic Pharmaceuticals: Patent Expiration and Low Global Utilization Rates Create Opportunities
Key Takeaways: · The generic pharmaceutical industry will benefit from a patent expiry “mountain” in 2015. · Penetration and utilization rates of generics vary considerably by country. Japan, Italy, Spain, France, and Australia are most likely to see the greatest increases in generic penetration rates. · We expect further M&A activity in Japan, as global players seek to gain a generics stronghold in this under-penetrated, yet burgeoning pharmaceutical market. · Emerging market growth will offer significant opportunities for firms levered to Latin America and South Africa. · The potential for biosimilars remains a key catalyst for the group. · Ideas o Teva Pharma (TEVA) is our favorite idea in the generics space thanks primarily to its upside valuation potential and global position. We’re particularly big fans … Read more
There Is Milk At The Store
This article first appeared in the September edition of the High Yield Dividend Newsletter. For more information about this publication, please see here. “Now this is not the end. It is not even the beginning of the end. But it is, perhaps, the end of the beginning.” — Winston Churchill By Brian Nelson, CFA Very few of us could have imagined that we’d witness the bull market that began on that fateful day in March 2009 that might very well mark a generational low. In 2009, major investment banks around the globe were struggling to survive, and the fallout in the mortgage markets left the banks holding paper that nobody wanted to own, let alone buy. The global financial system … Read more
The “Hierarchy” of Valuentum Idea Generation
Let’s talk about this hierarchy of idea generation in this note. — A version of this article was sent to members previously. New content has been added. — Note: We continue to work to optimize the signal-to-noise ratio in our work, and we are evaluating expanding our update cycle to half-year periods to better bolster the signaling aspects of the Valuentum Buying Index (VBI). In our widely-read case study (see here), the VBI showed its ability to rank equity returns over a forward 12-month period, and we think a migration to less-frequent updating may make the most sense to better capture the forward-looking dynamics of the system. We think this will help weed out false breakouts and other noise that could be harmful. You shouldn’t think of … Read more
Dividend Increases/Decreases for the Week Ending April 29
Below we provide a list of firms that raised/lowered their dividends during the week ending April 29. The dividend reports of covered firms on this list will be updated shortly with the new information. To access our dividend reports use the ‘Symbol’ search box in our website header. Firms Raising Their Dividends This Week abaxis (ABAX): now $0.12 per share quarterly dividend, was $0.11. Allegiant Travel Company (ALGT): now $0.70 per share quarterly dividend, was $0.30. American National Insurance (ANAT): now $0.82 per share quarterly dividend, was $0.80. AmeriGas Partners (APU): now $0.94 per share quarterly dividend, was $0.92. Ameriprise Financial (AMP): now $0.75 per share quarterly dividend, was $0.67. Apple (AAPL): now $0.57 per share quarterly dividend, was $0.52. … Read more
Have Bristol-Myers Squibb’s Shares Finally Found Support?
Image Source: kennijima By Alexander J. Poulos and Brian Nelson, CFA The pharmaceutical industry remains an area of innovation with numerous life-altering therapies brought forth to treat the many afflictions that plague us. The industry lifeblood remains the tenuous path of research and study. There is not a foolproof way to predict how a compound will respond until full clinical trials are completed and analyzed, and even successful commercialization cannot be guaranteed should a drug be approved, regardless of the time and costs invested. A later stage clinical failure, for example, could devastate a smaller company, with its equity never to recover. That’s in part why we tend to prefer larger, more diversified, entities within the pharma/biotech arena as the … Read more
Update on Wuhan 2019 Novel Coronavirus Outbreak: 31,000+ Infections, 630+ Deaths
Image Source: 2019-nCoV, Centers for Disease Control and Prevention The number of infections and deaths related to the Wuhan 2019 Novel Coronavirus has surged since our last update, but we maintain our view that investors should keep a level head. We continue to wait to add protection to the newsletter portfolios as the market absorbs a massive liquidity injection from the PBOC. By Brian Nelson, CFA The week of trading ending February 7 was a very strange one. Last Sunday, one could have only expected that given the news related to the Wuhan 2019 Novel Coronavirus outbreak, the bad news related to airlines (JETS) and aerospace players–Boeing (BA), in particular–and the speculative frenzy associated with Tesla’s (TSLA) rise, that the … Read more
Update: Johnson & Johnson Is A Stellar Company With Ample Upside
Summary We view Johnson & Johnson’s capital appreciation and dividend growth upside potential quite favorably. The top end of our fair value estimate range sits at $206 per share of JNJ. In this article, we cover Johnson & Johnson’s stellar financial performance, recent guidance boosts, and some of its legal hurdles. Johnson & Johnson announced on November 12 that it would spinoff its consumer-facing operations while retaining its medical devices and pharmaceutical operations. —- By Valuentum Analysts —– On October 19, Johnson & Johnson (JNJ) reported third-quarter earnings for fiscal 2021 (period ended October 3, 2021) that missed consensus top-line estimates but beat consensus bottom-line estimates. The healthcare giant also raised its full-year guidance (again) for fiscal 2021 as its ‘Pharmaceutical’ segment is growing at a … Read more
Update: Frequently Asked Questions About Valuentum Securities, Inc.
What is Valuentum Securities? Valuentum (val∙u∙n∙tum) [val-yoo-en-tuh-m] Securities Inc. is an independent investment research publisher, offering premium equity reports and dividend reports, as well as commentary across all sectors/companies, a Best Ideas Newsletter (spanning market caps, asset classes), a Dividend Growth Newsletter, modeling tools/products, and more. Independence and integrity remain our core, and we strive to be a champion of the investor. Valuentum is based in the Chicagoland area. Valuentum is not a money manager, broker, or financial advisor. Valuentum is a publisher of financial information. How do I subscribe to Valuentum’s investment research services? 1) Click the following link: signup-page. 2) Select your membership plan. 3) Enter your contact details. 4) Click ‘Sign Up.’ 5) Complete your purchase. 6) Your payment profile may be recurring, so please check … Read more